戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 1 provided good imaging of NHL and favorable radiation dosimetry.
2 fter infusion to assess pharmacokinetics and radiation dosimetry.
3 a is a general approach for medical internal radiation dosimetry.
4  whole-body biodistribution and to calculate radiation dosimetry.
5 racer biodistribution, pharmacokinetics, and radiation dosimetry.
6 racer biodistribution, pharmacokinetics, and radiation dosimetry.
7 (64)Cu-FBP8 administration to estimate human radiation dosimetry.
8 th (18)F-FPEB, we performed studies of human radiation dosimetry.
9  alternative with improved image quality and radiation dosimetry.
10 easure their comparative biodistribution and radiation dosimetry.
11 on, tissue iNOS levels, and calculated human radiation dosimetry.
12 al assessments of pharmacokinetics and organ radiation dosimetry.
13 entation; 2) 10 days of personal ultraviolet radiation dosimetry; 3) a sun exposure and physical acti
14                      Methods: To approximate radiation dosimetry, 4 patients with metastatic castrati
15 re conducted to evaluate biodistribution and radiation dosimetry after intravenous injection of (18)F
16  on Radiological Protection recommendations, radiation dosimetry analysis was performed using IDAC-Do
17 ated in 2 studies: in the first study, human radiation dosimetry and biodistribution of (11)C-metform
18 erformed over 48 h for calculation of tissue radiation dosimetry and for evaluation of clinical safet
19                                Understanding radiation dosimetry and its potential for deleterious he
20                            We determined its radiation dosimetry and relationships to pretherapeutic
21 OLINDA/EXM package to calculate the internal radiation dosimetry and the subjects' effective dose.
22 uorodeoxyglucose (FDG), to contribute to its radiation dosimetry and to define a suitable proxy for a
23 clusion: On the basis of the safety profile, radiation dosimetry, and biodistribution of [(18)F]SYN2,
24 al study aimed to assess the safety profile, radiation dosimetry, and biodistribution of a potential
25 mical parameters before and after treatment, radiation dosimetry, and complications were recorded.
26         Methods: Pharmacokinetics, toxicity, radiation dosimetry, and efficacy were assessed in GRPR-
27                             Biodistribution, radiation dosimetry, and semiquantitative evaluation of
28                     Safety, biodistribution, radiation dosimetry, and the most appropriate imaging ti
29                  Data on chemical stability, radiation dosimetry, and toxicity of FCH were obtained.
30 d at evaluating the safety, biodistribution, radiation dosimetry, and tumor-imaging potential of (131
31          Controversies regarding the role of radiation dosimetry are discussed as well.
32                                              Radiation dosimetry assessment was performed using pharm
33 matically investigate the safety profile and radiation dosimetry at varying PAH plasma concentrations
34 tives of this phase I study were to evaluate radiation dosimetry, biodistribution, human safety, tole
35 human experience with (18)F-FEOBV, including radiation dosimetry, biodistribution, tolerability and s
36                                              Radiation dosimetry calculations determined pharmacokine
37                                              Radiation dosimetry calculations indicate that there is
38          The whole-body and individual organ radiation dosimetry characteristics and pharmacologic sa
39    The 188Re(Sn)HEDP has biodistribution and radiation dosimetry characteristics that are similar to
40                 Human normal-organ kinetics, radiation dosimetry, clinical safety, and imaging effica
41                             Medical internal radiation dosimetry constitutes a fundamental aspect of
42 herapy, research and development in internal radiation dosimetry continue to advance both at academic
43 alization tools for environmental telemetry, radiation dosimetry data and 'omics analyses.
44 F-FETrp tumoral uptake, biodistribution, and radiation dosimetry data provide strong preclinical evid
45                    Clinical data and HP axis radiation dosimetry data were obtained from 88 eligible
46 e of this study is to numerically assess the radiation dosimetry due to particles decaying in the res
47 were acquired over 6 h for (18)F-MNI-659 and radiation dosimetry estimated with OLINDA.
48                                      Revised radiation dosimetry estimates for 201Tl-thallous chlorid
49                                              Radiation dosimetry estimates for 90Y-J591 calculated on
50                                              Radiation dosimetry estimates indicate that more than 40
51                                              Radiation dosimetry estimates indicated that the dose-li
52                                              Radiation dosimetry estimates were calculated using avai
53                                              Radiation dosimetry estimates were calculated using the
54    The (18)F-PEG(6)-IPQA pharmacokinetic and radiation dosimetry estimates were determined using volu
55 8)F-MNI-800 from 2 adult rhesus macaques for radiation dosimetry estimates.
56      Whole-body PET images were acquired for radiation dosimetry estimates.
57 conventional formulations, and the predicted radiation dosimetry estimations for some organs varied s
58                  (124)I-omburtamab PET-based radiation dosimetry estimations revealed mean (+/-SD) ab
59                                          The radiation dosimetry for (11)C-CNS5161 for a standard sin
60                                          The radiation dosimetry for (111)In and (177)Lu compared fav
61                                          The radiation dosimetry for (18)F-FETrp determined from the
62        We herein assess the cytotoxicity and radiation dosimetry for (68)Ga-NOTA-UBI and a first-in-h
63 aim of this study was to derive PET/CT-based radiation dosimetry for (89)Zr-cetuximab, with special e
64 macokinetic data and 90Y physical constants, radiation dosimetry for 90Y-21T-BAD-Lym-1 was determined
65 s, metabolomics) data, detailed metadata and radiation dosimetry for a variety of model organisms.
66 cements in patient selection, technique, and radiation dosimetry for radiation segmentectomy have red
67                         This article reviews radiation dosimetry for radiopharmaceuticals and also CT
68 dy was to determine the pharmacokinetics and radiation dosimetry for the initial 131I-Lym-1 therapy d
69                             We estimated the radiation dosimetry for this tracer from data gathered i
70                             We estimated the radiation dosimetry for this tracer using data obtained
71  whole-body biodistribution and estimate the radiation dosimetry from (11)C-CURB scans in humans.
72                                              Radiation dosimetry in "sensitive" populations, includin
73 ion of 99mTc-labeled anti-SSEA-1 and perform radiation dosimetry in 10 healthy human volunteers.
74 examined the (18)F-FdCyd biodistribution and radiation dosimetry in 5 human subjects enrolled in comp
75 was evaluated for distribution, binding, and radiation dosimetry in a healthy cynomolgus monkey.
76  its whole-body biokinetics and estimate its radiation dosimetry in healthy human volunteers.
77 as to measure its whole-body biokinetics and radiation dosimetry in healthy human volunteers.
78      This study was designed to evaluate the radiation dosimetry in human subjects for a new radiopha
79 y was to assess safety, biodistribution, and radiation dosimetry in humans for the highly selective s
80 background signal, biosafety, and acceptable radiation dosimetry in humans.
81                                              Radiation dosimetry in mice indicated [(11)C]CPPC to be
82 onuclides and the need for greater accuracy, radiation dosimetry in nuclear medicine is evolving from
83                               Calculation of radiation dosimetry in targeted nuclear medicine therapi
84                               Calculation of radiation dosimetry in targeted nuclear medicine therapi
85 rt the safety, biodistribution, and internal radiation dosimetry, in humans with thyroid cancer, of (
86                      Laboratory reporting of radiation dosimetry is a critical component of creating
87               Assessment of distribution and radiation dosimetry is a key element in optimizing such
88 e ovarian dose model is preferred if ovarian radiation dosimetry is available.
89                      The basic hypothesis in radiation dosimetry is that the energy deposited by ioni
90                         Assessments included radiation dosimetry, kinetic modeling, test-retest varia
91 s and assessed the feasibility of generating radiation dosimetry maps in liver regions with high and
92 paclitaxel PET/CT tumor imaging and provides radiation dosimetry measurements in humans.
93  using a single-compartment medical internal radiation dosimetry (MIRD) model.
94 e calculational ease of the Medical Internal Radiation Dosimetry (MIRD) system with the additional in
95 ole-body PET/CT was used to characterize the radiation dosimetry of (11)C-DPA-713, a specific PET lig
96 , we measured the whole-body biokinetics and radiation dosimetry of (123)I-IMPY in AD patients and co
97 s the pharmacokinetics, biodistribution, and radiation dosimetry of (124)I-omburtamab administered in
98 describe the initial clinical experience and radiation dosimetry of (18)F-DCFBC in men with metastati
99                                          The radiation dosimetry of (18)F-FBAU was evaluated using th
100 nteers underwent imaging to verify the human radiation dosimetry of (18)F-FTT.
101 cokinetics, biodistribution, metabolism, and radiation dosimetry of (18)F-PEG(6)-IPQA in nonhuman pri
102 as to evaluate the administration safety and radiation dosimetry of (18)F-PSMA-11.
103 n: The safety, biodistribution, and internal radiation dosimetry of (18)F-rhPSMA-7.3 are considered f
104      Here, we evaluated the safety and human radiation dosimetry of (64)Cu-LLP2A for potential use in
105  evaluate the biodistribution, kinetics, and radiation dosimetry of (64)CuCl2 in humans and to assess
106 iodistribution, kinetics of the lesions, and radiation dosimetry of (64)CuCl2 were evaluated.
107 measure the biodistribution and estimate the radiation dosimetry of (68)Ga-ABY-025 for 2 different pe
108 lism, pharmacokinetics, biodistribution, and radiation dosimetry of (68)Ga-bombesin antagonist (68)Ga
109              The whole-body distribution and radiation dosimetry of (68)Ga-pentixafor were evaluated.
110                                   Whole-body radiation dosimetry of 11C-raclopride was performed in h
111        This study evaluates the kinetics and radiation dosimetry of 18F-FCH using murine and human bi
112 etics for 67Cu and 64Cu was assumed, and the radiation dosimetry of 64Cu was assessed using quantitat
113 ding 131I-labeled monoclonal antibodies, the radiation dosimetry of 90Y-2-iminothiolane-2-[p-(bromoac
114                                          The radiation dosimetry of 90Y-J591 was estimated based on b
115                      This study assessed the radiation dosimetry of 99mTc-labeled ethylene dicysteine
116 nvestigated the safety, biodistribution, and radiation dosimetry of a novel (18)F-labeled radiohybrid
117 investigated the whole-body distribution and radiation dosimetry of both radiotracers in humans.
118                           The tau values for radiation dosimetry of FDG in the heart, lungs, liver an
119      The present study sought to measure the radiation dosimetry of IPT in seven healthy human volunt
120 man safety, whole-organ biodistribution, and radiation dosimetry of LMI1195 were evaluated in a phase
121 y is to evaluate the PET biodistribution and radiation dosimetry of the fibroblast activation protein
122                  Whole-body distribution and radiation dosimetry of this new probe were evaluated.
123 e safety, tolerability, biodistribution, and radiation dosimetry of this radiopharmaceutical.
124 gistic regression models considering ovarian radiation dosimetry or prescribed pelvic and abdominal r
125                                     From the radiation dosimetry perspective, the apoptosis imaging a
126                                              Radiation dosimetry PET/CT experiments indicated that mo
127                             The estimates of radiation dosimetry, pharmacokinetic parameters, and saf
128                            Therefore, from a radiation dosimetry point of view, HD is preferred for P
129                            Therefore, from a radiation dosimetry point of view, there is no preferenc
130                The findings suggest that the radiation dosimetry profile for this new infection imagi
131 uptake reflects PARP expression and that its radiation dosimetry profile is compatible with those of
132 rt the safety, biodistribution, and internal radiation dosimetry profiles of (18)F-D4-FCH in 8 health
133 rt the safety, biodistribution, and internal radiation dosimetry profiles of (18)F-ICMT-11 in 8 healt
134               We present the first-in-humans radiation dosimetry results and biodistribution of (18)F
135 sed in conjunction with the Medical Internal Radiation Dosimetry schema to: estimate absorbed doses i
136 abeled (18)F-FNP-59 is described, and rodent radiation dosimetry studies and in vivo imaging in New Z
137   Here, we present a PET biodistribution and radiation dosimetry study of (68)Ga-FAPI-46 in cancer pa
138    Here we present a PET biodistribution and radiation dosimetry study of (68)Ga-FAPI-46 in cancer pa
139 indicated that both disposition kinetics and radiation dosimetry support its clinical use for imaging
140                           In cancer therapy, radiation dosimetry supports treatment planning, dose-re
141                                              Radiation dosimetry to adult reproductive organs was les
142 solution, manufacturing challenges, and high radiation dosimetry to patients that have limited their
143                                              Radiation dosimetry to the HP axis was associated only w
144 d after infusion to assess pharmacokinetics, radiation dosimetry, toxicity and tumor regression.
145 doses and an ovarian dose model with ovarian radiation dosimetry using logistic regression were selec
146                                              Radiation dosimetry was acceptable, with effective doses
147                                              Radiation dosimetry was assessed using the MIRD method.
148                                              Radiation dosimetry was calculated using mouse biodistri
149                                              Radiation dosimetry was calculated using the OLINDA/EXM
150 tative organ distribution was determined and radiation dosimetry was calculated.
151 , 24, and 48 h after injection, and internal radiation dosimetry was derived for the tumor and organs
152                 In advance of human studies, radiation dosimetry was determined in nonhuman primates.
153                                              Radiation dosimetry was estimated by whole-body PET of a
154                                              Radiation dosimetry was favorable (effective dose, 5.2 m
155                                              Radiation dosimetry was performed to estimate radiation
156                                   Otherwise, radiation dosimetry was, on average, remarkably similar
157 methods to simplify and potentially automate radiation dosimetry we hope to accelerate the understand
158 methods to simplify and potentially automate radiation dosimetry, we hope to accelerate the understan
159                      The biodistribution and radiation dosimetry were assessed by serial whole-body P
160                   Additionally, toxicity and radiation dosimetry were assessed.
161 the dosimetry group, the biodistribution and radiation dosimetry were calculated using whole-body PET
162            Spatial distributions of internal radiation dosimetry were compared for different radionuc
163 linical setting, whole-body distribution and radiation dosimetry were evaluated.
164         During therapy, pharmacokinetics and radiation dosimetry were evaluated.
165 based biodistribution, pharmacokinetics, and radiation dosimetry were performed on nonhuman primates.
166 vo autoradiography, biochemical analyses and radiation dosimetry were performed.
167                         Pharmacokinetics and radiation dosimetry were, on average, remarkably similar
168                                          For radiation dosimetry, whole-body scans were performed at
169           (11)C-sarcosine showed a favorable radiation dosimetry with an effective dose estimate of 0

 
Page Top